Background/Objectives: Triple-negative breast cancer is difficult to treat due to the absence of hormone receptors and Her2neu. Sacituzumab govitecan is a new therapeutic approach that uses an antibody directed against the Trop-2 antigen present in solid epithelial tumors, linked to the active metabolite SN-38, similar to irinotecan, to specifically target cancer cells while minimizing damage to healthy cells. The objective of the present review was to evaluate the efficacy and safety of sacituzumab govitecan as a single treatment in patients with triple-negative breast cancer and to compare its results with the standard conventional chemotherapy regimen currently used in this disease. Methods: A systematic review of randomized clinical trials of sacituzumab govitecan was performed. The search was performed in Medline (PubMed), Web of Science, and Cochrane from September 2022 to January 2024. Results: Thirty-eight articles are included and evaluated according to inclusion and exclusion criteria corresponding to the two most relevant clinical trials, including specific analyses of cohorts and subgroup study arms within these trials. Data from more recent clinical trials are also reviewed. Conclusions: The efficacy results showed a significantly greater clinical benefit with sacituzumab govitecan compared to standard chemotherapy in patients with triple-negative breast cancer. This drug will become a treatment of substantial impact in future treatment guidelines for this type of cancer.
背景/目的：三阴性乳腺癌因缺乏激素受体和Her2neu而难以治疗。Sacituzumab govitecan是一种新型疗法，通过靶向实体上皮肿瘤中存在的Trop-2抗原的抗体，与伊立替康的活性代谢物SN-38连接，从而特异性靶向癌细胞，同时最大程度减少对健康细胞的损伤。本综述旨在评估sacituzumab govitecan作为单一疗法治疗三阴性乳腺癌患者的疗效和安全性，并将其结果与目前用于该疾病的标准常规化疗方案进行比较。方法：对sacituzumab govitecan的随机临床试验进行了系统综述。检索于2022年9月至2024年1月在Medline（PubMed）、Web of Science和Cochrane数据库中进行。结果：根据纳入和排除标准，共纳入并评估了38篇文章，对应两项最相关的临床试验，包括对这些试验中的队列和亚组研究组的特定分析。同时，还回顾了近期临床试验的数据。结论：疗效结果显示，与标准化疗相比，sacituzumab govitecan在三阴性乳腺癌患者中显示出显著更高的临床获益。该药物将成为未来此类癌症治疗指南中具有重要影响的治疗方案。
Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials
肿瘤(癌症)患者之家